Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, how many people with (a) relapsed diffuse large B-cell lymphoma and (b) children with relapsed acute lymphoblastic leukaemia have received CAR-T therapies in each of the last five years.
Chimeric Antigen Receptor T-cell (CAR-T) therapies have been available since November 2018 (acute lymphoblastic leukaemia) and December 2018 (relapsed DLBCL). The first patients were reinfused in January 2019. Therefore, the only data we have for the last five years is for 2019 and 2020. We do not have numbers for people treated in trials.
Number of people with diffuse large B-cell lymphoma that have received CAR-T therapies in each of the last five years:
Indication | 2019 | 2020* |
Diffuse large B cell lymphoma | 133 | Suppressed due to small numbers |
Note: *Up to 21 January 2020
Number of children with relapsed acute lymphoblastic leukaemia that have received CAR-T therapies in each of the last five years:
Indication | 2019 | 2020* |
Acute lymphoblastic leukaemia | 20 | Suppressed due to small numbers |
Note: *Up to 21 January 2020
We are unable to provide the numbers of people with relapsed diffuse large B-cell lymphoma and children with relapsed acute lymphoblastic leukaemia that have received CAR-T therapy at each Joint Accreditation Committee ISCT-Europe & EBMT (JACIE) accredited treatment centre treatment due to small numbers and the possibility of patients being identified. This will be possible in the future when the number of patients treated increases.